Yale University
Dept. of Psychiatry
300 George Street
New Haven, CT
06511 USA

Tel: 203-785-2117

YUSM Logo

Research Clinics

Yale Depression Research Program | Antidepressant augmentation with AZD6765, an investigational drug for treatment resistant depression

A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects with Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
[HIC#0811004498]
Clinicaltrials.gov Identifier: NCT00781742

Many patients with depression do not respond to current available antidepressant treatments or experience a recurrence of symptoms once improvement has been achieved. The primary purpose of this study is to determine whether a superior antidepressant effect can be achieved after multiple intravenous infusions of AZD6765 versus placebo when given in combination with your current FDA approved antidepressant. AZD6765 is a drug developed by AstraZeneca for the treatment of moderate to severe depression, and it has already been shown to help some research subjects with treatment resistant depression in a smaller phase IIa study performed in our clinic. This is an outpatient study in which research subjects will be randomly assigned to treatment groups that will either receive 100 mg AZD6765, 150 mg AZD6765, or placebo in addition to their current antidepressant. Infusions will be given at a clinical research unit at Yale New Haven Hospital over a three week period (two or three times per week). Each study visit during these three weeks will last between two to four hours. Subjects will then be followed in our clinic for an additional five weeks to monitor their depression symptoms.

Last modified: March 13, 2009